New study evaluates the awareness of novel advanced therapies among family medicine residents. The findings of the study are published in the journal PLOS ONE. A recent study conducted jointly by the Tissue Engineering Research Group of the Department of Histology and the Family Medicine Unit of the University of Granada (UGR) has highlighted the conceptual, attitudinal, and procedural profile of resident hospital doctors specializing in Family Medicine, in relation to the so-called advanced therapies.
‘Family medicine specialists play an important role as health educators. Hence, their residency programs should include new knowledge related to advanced therapies.’According to the European Medicines Agency, such therapies--cell therapy, gene therapy, and tissue engineering--constitute a range of innovative therapies whose application presents extremely rigorous biofabrication requirements.
Tweet it Now
The progressive increase in demand for such therapies and consultations about their possible use by patients with different pathologies calls for relevant health education about them--a task in which Family Doctors have an important role to play.
Little training in this area
The study highlights a perception among resident doctors that they are receiving insufficient training, both at a conceptual level and also in terms of the regulatory framework in this area. It also notes a highly positive attitude towards the use and application of such therapies in hospitals and toward greater research into the topic. Furthermore, the findings point to a clear preference among these doctors for the necessary drugs to be developed within research centers, whereas the current regulation requires biofabrication to be carried out on GMP (Good Manufacturing Practice) approved premises, wherever these may be located.
The resident doctors consulted in the study expressed serious reservations about the monitoring of the patients undergoing such treatments being conducted in health centers, and about the fact that the biofabrication process is linked to the pharmaceutical industry.
Before the study, the UGR's Tissue Engineering Research Group successfully designed artificial corneas and human skin as advanced therapy treatments. These were developed at the university and later transferred to clinical practice.